|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumors with NF1/Ch17 loss were predominantly adult GBM (4/5); lacked EGFR amplification (0/4), strong p53 immunolabeling (1/5), or IDH1 (R132H) protein expression (0/5); but expressed the mesenchymal marker podoplanin in 4/5.
|
26190195 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
While serving as a marker for tumor progression and modulating invasion in various neoplasms, little is known about podoplanin function in gliomas.
|
26339454 |
2015 |
|
Glioma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Patients/Methods In a prospective cohort study, intratumoral IDH1 R132H mutation and podoplanin were determined in brain tumor specimens (mainly glioma) by immunohistochemistry.
|
29676036 |
2018 |
|
Glioblastoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Tumors with NF1/Ch17 loss were predominantly adult GBM (4/5); lacked EGFR amplification (0/4), strong p53 immunolabeling (1/5), or IDH1 (R132H) protein expression (0/5); but expressed the mesenchymal marker podoplanin in 4/5.
|
26190195 |
2015 |
|
Glioblastoma Multiforme
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Tumors with NF1/Ch17 loss were predominantly adult GBM (4/5); lacked EGFR amplification (0/4), strong p53 immunolabeling (1/5), or IDH1 (R132H) protein expression (0/5); but expressed the mesenchymal marker podoplanin in 4/5.
|
26190195 |
2015 |
|
Human immunodeficiency virus II infection
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Hence, the aim of this study was to estimate the prevalence of HIV-2 infection and its genotype in Maputo, Mozambique.HIV-infected individuals (N = 1,200) were consecutively enrolled and screened for IgG antibodies against HIV-1 gp41 and HIV-2 gp36 using peptide-based enzyme immunoassays (pepEIA).
|
21849066 |
2011 |
|
HIV-2 infection
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Hence, the aim of this study was to estimate the prevalence of HIV-2 infection and its genotype in Maputo, Mozambique.HIV-infected individuals (N = 1,200) were consecutively enrolled and screened for IgG antibodies against HIV-1 gp41 and HIV-2 gp36 using peptide-based enzyme immunoassays (pepEIA).
|
21849066 |
2011 |
|
Malignant mesothelioma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.
|
22784439 |
2013 |
|
Peritoneal Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.
|
22784439 |
2013 |
|
Carcinomatosis of peritoneal cavity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features.
|
22784439 |
2013 |
|
Respiratory Distress Syndrome, Adult
|
0.210 |
Biomarker
|
disease |
BEFREE |
Therefore the purpose of this study was to establish the role of CLEC-2 and its ligand podoplanin in a mouse model of ARDS.
|
28839100 |
2017 |
|
Respiratory Distress Syndrome, Adult
|
0.210 |
Biomarker
|
disease |
RGD |
Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs.
|
11790662 |
2002 |
|
Albuminuria
|
0.200 |
Biomarker
|
phenotype |
RGD |
Albuminuria developed starting at 6 wk of age and coincided with focal and segmental loss of podoplanin, increased expression of desmin, entrapment of albumin in affected podocytes, and focal and segmental foot process effacement at the ultrastructural level.
|
18199599 |
2008 |
|
Pneumonia, Bacterial
|
0.200 |
Biomarker
|
group |
RGD |
A type I cell-specific protein is a biochemical marker of epithelial injury in a rat model of pneumonia.
|
7864138 |
1995 |
|
Inflammation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Coexpression of RTI40 with alveolar epithelial type II cell proteins in lungs following injury: identification of alveolar intermediate cell types.
|
15849211 |
2005 |
|
Nephrosis
|
0.200 |
Biomarker
|
disease |
RGD |
Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis.
|
9327748 |
1997 |
|
Oligohydramnios
|
0.200 |
Biomarker
|
phenotype |
RGD |
Effects of oligohydramnios on lung growth and maturation in the fetal rat.
|
11839536 |
2002 |
|
Hyperoxia
|
0.200 |
Biomarker
|
phenotype |
RGD |
Protein nitration in rat lungs during hyperoxia exposure: a possible role of myeloperoxidase.
|
12922978 |
2003 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The validation cohort with 224 randomly matched cases from The Cancer Genome Atlas data set also displayed significantly shorter overall survival in the group with elevated <i>PDPN</i> mRNA (<i>p</i>=0.05).
|
29872344 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Blocking CLEC-2-podoplanin interaction may be a novel therapeutic strategy in patients with podoplanin-expressing cancer.
|
31808911 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
|
30418623 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Podoplanin seems to be a reliable means of discriminating lesions with epithelial dysplasia and could be introduced in routine practice as a marker to discriminate OLs at risk of developing cancer.
|
29588189 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we compared the MIB-1 labeling index of cancer cells in podoplanin (+) CAFs cases (n = 13) and podoplanin (-) CAFs cases (n = 14) using surgically resected adenocarcinoma specimens.
|
31319967 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer.
|
29765527 |
2018 |